tweetindex
EN

The ASCO Post

@ASCOPost · Huntington, NY · joined 15 Dec 2009

News and views from the world of clinical oncology and hematology

62 531Followers
4 489Following
35 351Posts total
5.6KViews on collected posts

Latest posts

🖥️ #ASCOAI: AI-based TIL scoring may offer a scalable prognostic tool in #BreastCancer, particularly where expert pathologist assessment is limited. Two studies evaluated computational approaches in triple-negative and HER2+ disease. 🔗 https://t.co/kVgVg6NjJB https://t.co/DKPn
768 views · 3 likes · 2 reposts · 1 replies Open on X →
💉Could less frequent tarlatamab dosing offer flexibility in #SCLC? In DeLLphi-309, 20 mg every 3 weeks and 30 mg every 4 weeks showed efficacy and safety consistent with the approved every-2-week regimen. 🗣️ Presented by Jonathan Goldman, MD at #WCLC26 🔗 https://t.co/qUkXCv082g h
1.3K views · 14 likes · 4 reposts · 1 replies Open on X →
💊 Cancer centers continue to navigate medication shortages. @NCCN reports 61% of responding centers required pharmacy- and physician-led mitigation strategies to keep patients on recommended doses and schedules. Learn more about the survey results 👉 https://t.co/VDvSJRRK6H ht
689 views · 1 likes · 1 reposts · 2 replies Open on X →
🫁 Phase 3️⃣ IMpower030: Perioperative atezolizumab + platinum chemo yielded a median event-free survival of 62.8 vs 34.9 months with chemotherapy alone in patients with resectable stage IIB–IIIB #NSCLC. 🗣️Presented by Benjamin Solomon, MD at #WCLC26 🔗 https://t.co/Pt9gFWgLQz
1.1K views · 6 likes · 4 reposts · 0 replies Open on X →
🆕 research suggests inherited genetics may help classify therapy-related #myeloidneoplasms and identify patients who could benefit from personalized risk assessment, genetic counseling & closer monitoring. 🔹Francesc Solé, PhD (@SoleKiko | @BloodAdvances https://t.co/5N928PuvnP h
1K views · 1 likes · 0 reposts · 0 replies Open on X →
🏥 #ASCOAI: As #AI reshapes #cancercare, patients must remain at the center. @jamecancerdoc of @ClevelandClinic discusses why AI’s potential should be measured by whether it can expand access to affordable, high-quality care. Watch the video ➡️ https://t.co/a0xUTBZGIy https://
731 views · 1 likes · 0 reposts · 0 replies Open on X →

Against accounts of the same size

6 posts from the last 90 days, next to the 10K–100K follower range. below its peers on both reach and engagement.

Median views886this account927median for 10K–100K
Reach, %1.42%this account3.63%median for 10K–100K
Engagement, %0.68%this account1.52%median for 10K–100K
MetricThis accountMedian for 10K–100KRatio
Median views per post8869270.96×
Reach (views ÷ followers)1.42%3.63%0.39×
Engagement rate0.68%1.52%0.45×

Others in this range →   Compare with another account →   How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

73111 Sep
1K14 Sep
1.1K15 Sep
689
1.3K
768

Last 6 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.14%11 Sep
0.10%14 Sep
0.91%15 Sep
0.58%
1.56%
0.78%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes53.1%26 in total
Reposts22.4%11 in total
Replies8.2%4 in total
Quotes2.0%1 in total
Bookmarks14.3%7 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

Followers by day

12 Sep

Daily snapshots since 12 Sep 2026; the dashed line is the starting count.

Similar accounts